Ionis Pharmaceuticals IONS Pre-tax stock-based compensation cost
Pre-tax stock-based compensation cost at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's pre-tax stock-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's pre-tax stock-based compensation cost?
- Ionis Pharmaceuticals (IONS) reported pre-tax stock-based compensation cost of $43.28M in Q1 2026.
- How has Ionis Pharmaceuticals's pre-tax stock-based compensation cost changed year-over-year?
- Ionis Pharmaceuticals's pre-tax stock-based compensation cost increased by 45.6% year-over-year, from $29.72M to $43.28M.
- What is the long-term trend for Ionis Pharmaceuticals's pre-tax stock-based compensation cost?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's pre-tax stock-based compensation cost has grown at a 12.5% compound annual growth rate (CAGR), from $105.81M to $133.87M.